Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Defence Therapeutics Inc (DTC.CN)

Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,045
  • Shares Outstanding, K 45,537
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,193 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5100 +21.57%
on 10/09/24
0.6700 -7.46%
on 11/04/24
+0.0600 (+10.71%)
since 10/04/24
3-Month
0.4800 +29.17%
on 09/19/24
0.7900 -21.52%
on 08/06/24
-0.1100 (-15.07%)
since 08/02/24
52-Week
0.4800 +29.17%
on 09/19/24
2.9000 -78.62%
on 11/14/23
-2.0900 (-77.12%)
since 11/03/23

Most Recent Stories

More News
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Therapeutics Completes 1st Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence's Corporate Updates, Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Appoints New Interim Chief Executive Officer

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.4140 (-5.07%)
DTC.CN : 0.6200 (+12.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Key Turning Points

3rd Resistance Point 0.7967
2nd Resistance Point 0.7333
1st Resistance Point 0.6767
Last Price 0.6200
1st Support Level 0.5567
2nd Support Level 0.4933
3rd Support Level 0.4367

See More

52-Week High 2.9000
Fibonacci 61.8% 1.9756
Fibonacci 50% 1.6900
Fibonacci 38.2% 1.4044
Last Price 0.6200
52-Week Low 0.4800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar